Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)- therapy

Abstract

Objectives. Anti-tumour necrosis factor (TNF)-α therapies are considered category B drugs for pregnancy. Although sometimes prescribed to women of reproductive age, data in humans are limited with regard to safety for a developing fetus. The objectives of the present article are to report experience of anti-TNF-α use in pregnancy, and review the international literature.